The meta-analysis of RCTs revealed no significant difference in the risk of lymphoma between patients receiving anti-TNF-α therapy and patients on conventional treatments, with an overall RR of 1.43 (95% CI: 0.32–5.16) and I2 of 0%. This evidence concerns the gene TNF and lymphoma.